evaluation, and post-operative care. The specially trained team includes a retina specialist, corneal surgeon, low vision optometrist, and a low vision occupational therapist. The occupational therapist works with the patient post-operatively over several visits to teach them how to use his/her new vision. About end-Stage AmD More than 15 million Americans are affected by some form of macular degeneration, and approximately 2 million Americans have advanced forms of AMD with associated vision loss. The number of Americans afflicted with macular degeneration is expected to double with the rapid aging of the U.S. population. The telescope implant has been demonstrated in earlier clinical trials and in commercial use to improve quality of life for those with central vision loss in both eyes. It also may help patients in social settings as it may allow them to recognize faces and see the facial expressions of family and friends. The telescope implant is not a cure for End-Stage AMD. As with any medical intervention, potential risks and complications exist with the telescope implant. Possible side effects include decreased vision or vision impairing corneal swelling. The risks and benefits associated with the telescope implant are discussed in the Patient Information Booklet available at www. CentraSight.com and will be evaluated with each patient who might be a candidate for this study. “We developed the telescope implant to help older adults with severely impaired central vision live more independently and improve their vision. Hundreds of patients have experienced the CentraSight treatment program and learned to use their new, improved vision, effectively. We hope the results of this study will allow us to offer the telescope implant to an even broader population of patients who are currently excluded simply because they had a routine eye surgery in the past. We’re looking forward to advancing this study and analyzing the results.” Blake Michaels, President & CEO VisionCare, Inc. Patients and physicians can find more information about the IMT and related treatment program by calling Lynn Rinaldi, SupportSightSM Program Manager, at 1-866- 462-2852 or CentraSight at 1-855-550-1041. 1 Bennion, AE, Shaw, RL, Gibson, JM “What do we know about the experience of age related macular degeneration? A systematic review and meta- synthesis of qualitative research?” Social Science & Medicine. 75 (2012) 976-985. 19 Macula Vision Research Foundation Spring/Summer 2017 the macula vision research foundation (mvrf) is not a healthcare provider, and nothing in this newsletter is intended as a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified healthcare provider regarding any questions about your medical condition, medical devices, or treatment options.